CDKN2A and melanoma: Previously, we have engineered an inducible bitransgenic HRASV12-driven melanoma model possessing both activator (Tyr-rtTA) and reporter (Tet-HRASV12) transgenes on Ink4a/Arf−/− background (hereafter designated as “iHRAS*”)[35].